 The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography computed tomography 18F-NaF PETCT imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer. 